The safety and efficacy of antithrombotic therapy in patients undergoing cardiac rhythm device implantation: A meta-analysis

Europace

Volumn 17, Issue 7, 2015, Pages 1076-1084

  Yang, Xiaowei ^a   Wang, Zhongsu ^a   Zhang, Yong ^a   Yin, Xiangcui ^a   Hou, Yinglong ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Antiplatelet therapy; Bleeding complications; Cardiac rhythm devices implantation; Heparin bridging therapy; Meta analysis; Thromboembolic risk; Uninterrupted anticoagulation therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; HEPARIN; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL HEART PACEMAKER; BLEEDING; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG SAFETY; HEMATOMA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; META ANALYSIS; PRIORITY JOURNAL; PROSTHESIS IMPLANTATION; THROMBOEMBOLISM; ADVERSE EFFECTS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMORBIDITY; HEMORRHAGE; INCIDENCE; MULTICENTER STUDY; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

COMORBIDITY; DEFIBRILLATORS, IMPLANTABLE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INCIDENCE; PACEMAKER, ARTIFICIAL; RISK FACTORS; THROMBOEMBOLISM;

EID: 84936760603     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euu369     Document Type: Article

References (48)

1. Schulman PM, Rozner MA, Sera V, Stecker EC. Patients with pacemaker or implantable cardioverter-defibrillator. Med Clin North Am 2013;97:1051-75.
2. Thomas AC, Moser SA, Smutka ML, Wilson PA. Implantable defibrillation: eight years clinical experience. Pacing Clin Electrophysiol 1988;11:2053-8.
3. DeSantis G, Hogan-Schlientz J, Liska G, Kipp S, Sallee R, Wurster M et al. STABLE results: warfarin home monitoring achieves excellent INR control. Am J Manag Care 2014;20:202-9.
4. ChengJW. Updates in antiplatelet agents used in cardiovascular diseases. J Cardiovasc Pharmacol Ther 2013;18:514-24.
5. WiegandUKH, LeJeune D, Boguschewski F, Bonnemeier H, Eberhardt F, Bode HS F. Pockethematomaafter pacemakeror implantable cardioverter defibrillator surgery. Chest 2004;126:1177.
6. Cacoub P, Leprince P, Nataf P, Hausfater P, Dorent R, Wechsler B et al. Pacemaker infective endocarditis. Am J Cardiol 1998;82:480-4.
7. Thal S, Moukabary T, Boyella R, Shanmugasundaram M, Pierce MK, Thai H et al. The relationship between warfarin, aspirin, and clopidogrel continuation in the periprocedural period and the incidence of hematoma formation after device implantation. Pacing Clin Electrophysiol 2010;33:385-8.
8. Jamula E, Douketis JD, Schulman S. Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide. J Thromb Haemost 2008;6:1615-21.
9. Levy S. Current atrial fibrillation guidelines and therapy algorithms: are they adequate? J Interv Card Electrophysiol 2009;25:111-6.
10. Ahmed I, Gertner E, Nelson WB, House CM, Dahiya R, Anderson CP et al. Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation. Heart Rhythm 2010;7:745-9.
11. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD et al. Pacemaker or Defibrillator Surgery without Interruption of Anticoagulation. New Engl J Med 2013;368:2084-93.
12. Cano O, Muñoz B, Tejada D, Osca J, Sancho-Tello M, Olagüe J et al. Evaluation of a new standardized protocol for the perioperative management of chronically anticoagulated patients receiving implantable cardiac arrhythmia devices. Heart Rhythm 2012;9:361-7.
13. Cheng A, Nazarian S, Brinker JA, Tompkins C, Spragg DD, Leng CT et al. Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: a randomized clinical trial. Heart Rhythm 2011;8:536-40.
14. Ghanbari H, Feldman D, Schmidt M, Ottino J, Machado C, Akoum N et al. Cardiac resynchronization therapy device implantation in patients with therapeutic international normalized ratios. Pacing Clin Electrophysiol 2010;33:400-6.
15. Li H, Chen FC, Rea RF, Asirvatham SJ, PowelL BD, Friedman PA et al. No increased bleeding events with continuation of oral anticoagulation therapy for patients undergoing cardiac device procedure. Pacing Clin Electrophysiol 2011;34:868-74.
16. MilicD, Perisic Z, Zivic S, Stanojkovic Z, Stojkovic A, KaranovicNet al. Prevention of pocket related complications with fibrin sealant in patients undergoing pacemaker implantation who are receiving anticoagulant treatment. Europace 2005;7:374-9.
17. Perrin MJ, Vezi BZ, Ha AC, Keren A, Nery PB, Birnie DH. Anticoagulation bridging around device surgery: compliance with guidelines. Pacing Clin Electrophysiol 2012; 35:1480-6.
18. Tischenko A, Gula LJ, Yee R, Klein GJ, Skanes AC, Krahn AD. Implantation of cardiac rhythm devices without interruption of oral anticoagulation compared with perioperative bridging with low-molecular weight heparin. Am Heart J 2009;158:252-6.
19. Tolosana JM, Berne P, Mont L, Heras M, Berruezo A, Monteagudo J et al. Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial. Eur Heart J 2009;30:1880-4.
20. Ramirez A, Wall TS, Schmidt M, Selzman K, Daccarett M. Implantation of cardiac rhythm devices during concomitant anticoagulation or antiplatelet therapy. Expert Rev Cardiovasc Ther 2011;9:609-14.
21. Ghanbari H, Phard WS, Al-Ameri H, Latchamsetty R, Jongnarngsin K, Crawford T et al. Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices. Am J Cardiol 2012;110:1482-8.
22. Feng L, Li Y, Li J, Yu B. Oral anticoagulation continuation compared with heparin bridging therapy among high risk patients undergoing implantation of cardiac rhythm devices. Thromb Haemostasis 2012;108:1124-31.
23. Bernard ML, Shotwell M, Nietert PJ, Gold MR. Meta-analysis of bleeding complications associated with cardiac rhythm device implantation. Circ-Arrhythmia Elec 2012;5:468-74.
24. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. ACC/ AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8:651-745.
25. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. Anz J Surg 2003;73:712-6.
26. Kutinsky IB, Jarandilla R, Jewett M, Haines DE. Risk of hematoma complications after device implant in the clopidogrel era. Circ-Arrhythmia Elec 2010;3:312-8.
27. Tompkins C, Cheng A, Dalal D, Brinker JA, Leng CT, Marine JE et al. Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol 2010;55:2376-82.
28. Özcan KS, Osmonov D, Y?ld?r?m E, Altay S, Türkkan C, Ekmekci A et al. Hematoma complicating permanent pacemaker implantation: the role of periprocedural antiplatelet or anticoagulant therapy. J Cardiol 2013;62:127-30.
29. Cano O, Osca J, Sancho-Tello MJ, Olague J, Castro JE, Salvador A. Morbidity associated with three different antiplatelet regimens in patients undergoing implantation of cardiac rhythm management devices. Europace 2011;13:395-401.
30. Said SM, Esperer HD, Hahn J, BollmannA, Richter S, Rauwolf Tet al. Influence of oral antiplatelet therapy on hemorrhagic complications of pacemaker implantation. Clin Res Cardiol 2013;102:345-9.
31. Korantzopoulos P, Letsas KP, Liu T, Fragakis N, Efremidis M, Goudevenos JA. Anticoagulation and antiplatelet therapy in implantation of electrophysiological devices. Europace 2011;13:1669-80.
32. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e326S-50S.
33. NascimentoT, Birnie DH, Healey JS, VermaA, Joza J, BernierMLet al.Managing novel oral anticoagulants in patients with atrial fibrillation undergoing device surgery: Canadian survey. Can J Cardiol 2014;30:231-6.
34. Jennings JM, Robichaux R, Mcelderry HT, Plumb VJ, Gunter A, Doppalapudi H et al. Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin. J Cardiovasc Electr 2013;24:1125-9.
35. Kosiuk J, Koutalas E, Doering M, Sommer P, Rolf S, Breithardt OA et al. Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations. Europace 2014;16:1028-32.
36. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation 2012;126:343-8.
37. Przybylski A, Derejko P, Kwasniewski W, Urbanczyk-Swic D, Zakrzewska J, Orszulak W et al. Bleeding complications after pacemaker or cardioverterdefibrillator implantation in patients receiving dual antiplatelet therapy: Results of a prospective, two-centre registry. Neth Heart J 2010;18:230-5.
38. Lee CK, Yoo SY, HongMY, Jang JK. Antithrombotic or anti-platelet agents in patients undergoing permanent pacemaker implantation. Korean Circ J 2012;42:538.
39. Eisenberg MJ, Richard PR, Libersan D, Filion KB. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 2009;119: 1634-42.
40. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003;110: 255-8.
41. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007;115:2196-207.
42. Dreger H, Grohmann A, Bondke H, Gast B, Baumann G, Melzer C. Is antiarrhythmia device implantation safe under dual antiplatelet therapy? Pace 2010;33:394-9.
43. Arrebola MM, De la Cruz JP, Villalobos MA, Pinacho A, Guerrero A, Sanchez DLCF. In vitro effects of clopidogrel on the platelet-subendothelium interaction, platelet thromboxane and endothelial prostacyclin production, and nitric oxide synthesis. J Cardiovasc Pharmacol 2004;43:74-82.
44. Massimi I, Guerriero R, Lotti LV, Lulli V, Borgognone A, Romani F et al. Aspirin influences megakaryocytic gene expression leading to upregulation of multidrug resistance protein-4 in human platelets. Br J Clin Pharmacol 2014;78:1343-53.
45. Moshfegh K, Redondo M, Julmy F, Wuillemin WA, Gebauer MU, Haeberli A et al. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 2000;36: 699-705.
46. Tompkins C, Henrikson CA. Optimal strategies for the management of antiplatelet and anticoagulation medications prior to cardiac device implantation. Cardiol J 2011; 18:103-9.
47. Kirkfeldt RE, Johansen JB, Nohr EA, Jorgensen OD, Nielsen JC. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J 2014;35:1186-94.
48. Lee DS, Krahn AD, Healey JS, Birnie D, Crystal E, Dorian P et al. Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. J Am Coll Cardiol 2010;55:774-82.